Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Prostate Adenocarcinoma
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing…
- Trial name
- NCT03762759
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer, Sexual Dysfunction
High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer
RATIONALE: Highly focused ultrasound energy may be able to kill tumor cells by heating the tumor without affecting the surrounding tissue.
- Conditions
- Prostate Cancer, Sexual Dysfunction, Urinary Incontinence
- Trial name
- NCT00561314
- Testing
- questionnaire administration, biopsy, high-intensity focused ultrasound ablation
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- University College London Hospitals
Prostate Cancer
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255606
- Testing
- docetaxel, prednisone
- Where
- 19 sites in Finland, Ireland and 1 more
- Volunteers
- 360 people
- Sponsor
- Tampere University
Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread…
- Trial name
- NCT05050084
- Testing
- Bicalutamide, Buserelin, Darolutamide
- Where
- 576 sites in United States, Canada
- Volunteers
- 2,050 people
- Sponsor
- NRG Oncology
Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that was removed by surgery.
- Conditions
- Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02446366
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Prostate Cancer, BRCA1 Mutation
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or…
- Conditions
- Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma
- Trial name
- NePtune (NCT05498272)
- Testing
- Olaparib, LHRH agonist
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rana McKay, MD
Prostate Cancer, Prostate Adenocarcinoma
Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management
1. Using multiparametric MRI Ultrasound-guided or MRI-guided biopsies will allow more accurate sampling of the tumors and therefore will increase the rate of "progression" on early (first and second) surveillance biopsies and…
- Trial name
- MGM (NCT01838265)
- Testing
- Transrectal Ultrasound-Guided Biopsy, MRI Ultrasound Biopsy, Expanded Prostate Cancer index Composite Questionnaire
- Where
- United States
- Sponsor
- University of Miami
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05691465
- Testing
- Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE
- Where
- 13 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
This clinical trial studies the side effects of computed tomography (CT)-guided stereotactic body radiation therapy (SBRT) with intrafraction motion monitoring and to see how well it works in treating patients with prostate…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- ILLUSION (NCT06995053)
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative
EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
We perform a multicenter randomized controlled prospective study with superiority trial design, in which the polysaccharide ARISTA™ AH hemostat agent is applied to the neurovascular bundle areas after prostate removal, during…
- Conditions
- Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative, Erectile Function
- Trial name
- ARISTA (NCT06822036)
- Testing
- Arm A - Application of 5g of ARISTA™ AH
- Where
- 3 sites in Germany
- Volunteers
- 362 people
- Sponsor
- St. Antonius Hospital Gronau
Prostate Cancer, Prostate Adenocarcinoma
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Patients will receive a single dose of 68Ga-PSMA-11 and undergo a PET/CT or PET/MRI imaging study.
- Trial name
- NCT05197257
- Testing
- Ga-PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of Colorado, Denver
Intraprostatic Prostate Cancer
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients…
- Trial name
- NCT07142967
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00096304
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Medical University of South Carolina
Male Breast Carcinoma, Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the…
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT02206334
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- NRG Oncology
Prostate Cancer, Adenocarcinoma of the Prostate
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01174199
- Testing
- vorinostat, temsirolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004026
- Testing
- CT-2584, chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- CTI BioPharma